Amgen Reveals Post-Hoc Data For Its KRAS Inhibitor In Lung Cancer Patients

Amgen Inc AMGN announced results from two analyses of the Phase 2 CodeBreaK 100 trial evaluating Lumakras (sotorasib).
Lumakras, a KRASG12C inhibitor, is approved in the U.S. for previously treated patients with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC).
Related Content: Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer.
In a post-hoc analysis of 40 patients, Lumakras achieved a 77.5% disease control rate (DCR), similar to patients without brain metastases.
A median progression-free survival (PFS) of 5.3 months and median overall survival (OS) of 8.3 months were observed.
In patients evaluable by Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, 14 of 16 patients (88%) maintained intracranial disease control of their stable brain lesions during Lumakras therapy with two achieving complete responses of non-target lesions.
The safety profile of Lumakras in the brain metastases group was consistent with previous reports.
Amgen is enrolling patients with active brain metastases in an arm of the CodeBreaK 101 study.
Price Action: AMGN stock is down 0.41% at $219.97 during the premarket session on the last check Thursday.